NCT06777316 - A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

January 22, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

June 30, 2027

Conditions

Intrahepatic Cholangiocarcinoma (Icc)CholangiocarcinomaOther Solid Tumors, AdultFGFR2 Gene Fusion/RearrangementFGFR2 Gene AmplificationFGFR2 Gene Short VariantsFGFR3 Gene Fusion/RearrangementFGFR3 Gene AmplificationFGFR3 Gene Short VariantsFGFR2 Genetic AlterationsFGFR3 Genetic AlterationsAdvanced Solid Tumors

Interventions

DRUG

CGT4859

CGT4859 is a selective FGFR2/3 inhibitor

Trial Locations (15)

19111

RECRUITING

Fox Chase cancer Center, Philadelphia

32224

RECRUITING

Mayo Clinic Jacksonville, Jacksonville

33612

RECRUITING

Moffitt Cancer Center, Tampa

37203

RECRUITING

Tennessee Oncology, Nashville

44195

RECRUITING

Taussig Cancer Center - Cleveland Clinic, Cleveland

45219

RECRUITING

The Christ Hospital, Cincinnati

55905

RECRUITING

Mayo Clinic Rochester, Rochester

60637

RECRUITING

University of Chicago Medicine Comprehensive Cancer Center, Chicago

77030

RECRUITING

MD Anderson Cancer Center, Houston

84112

RECRUITING

Huntsman Cancer Institute - University of Utah, Salt Lake City

85253

RECRUITING

Mayo Clinic Scottsdale, Scottsdale

94305

RECRUITING

Stanford Cancer Institute, Palo Alto

02114

RECRUITING

Massachusetts General Hospital, Boston

T6G 1Z2

RECRUITING

Cross Cancer Institute, Edmonton

M5G 2C4

RECRUITING

Princess Margaret Cancer Centre - UHN, Toronto